Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).
Justin C BrownSui ZhangFang-Shu OuAlan P VenookDonna NiedzwieckiHeinz-Josef LenzFederico InnocentiBert H O'NeilJames E ShawBlase N PoliteCrystal S DenlingerJames N AtkinsRichard M GoldbergKimmie NgRobert J MayerCharles D BlankeEileen M O'ReillyCharles S FuchsJeffrey A MeyerhardtPublished in: JNCI cancer spectrum (2019)
Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or metastatic CRC. Patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly to patients without diabetes.
Keyphrases
- type diabetes
- cardiovascular disease
- metastatic colorectal cancer
- glycemic control
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- small cell lung cancer
- poor prognosis
- peritoneal dialysis
- coronary artery disease
- risk factors
- patient reported outcomes
- adipose tissue
- long non coding rna
- metabolic syndrome
- weight loss
- insulin resistance